Question · asked by 1 review
Summary of findings ‐ ivacaftor vs placebo: QoL (CFQ‐R) Respiratory domain
- Population
- adults and children with cystic fibrosis and with the F508del CFTR mutation
- Intervention
- Summary of findings ‐ ivacaftor
- Comparison
- placebo
- Outcome
- QoL (CFQ‐R) Respiratory domain
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Summary of findings ‐ ivacaftor vs placebo QoL (CFQ‐R) Respiratory domain · adults and children with cystic fibrosis and with the F508del CFTR mutation Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis (2019) · Cochrane Headline outcomes only | no estimate extracted | 1 study · 140 participants | Moderate |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis 2019 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Summary of findings ‐ ivacaftor vs placebo · adults and children with cystic fibrosis and with at least one R117H CFTR mutation · 1 review
- Summary of findings ‐ ivacaftor vs placebo · adults and children with cystic fibrosis and with at least one G551D CFTR mutation · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.